{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T09:04:33Z","timestamp":1723280673740},"reference-count":22,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>von Recklinghausen disease (vRD), more widely known as neurofibromatosis type 1, belongs to a group of genetic disorders and it is considered to be the most common genodermatosis. The disease has an autosomal dominant pattern of inheritance that involves mutations within the <jats:italic>NF1<\/jats:italic> gene located on chromosome 17 in locus q11.2. The product of the <jats:italic>NF1<\/jats:italic> gene is neurofibromin and the protein is well known to be a tumor suppressor factor. This counteracts possible overactivity of RAS (protein)\/MAPK (mitogen-activated protein kinase) and RAS\/PI3K\/AKT\/mTOR (phoshatydyloinositol-3-kinase\/V-akt murine thy-moma viral oncogene homologue\/mammalian target of rapamycin) signaling transduction pathways, preventing from uncontrolled cell proliferation and subsequent tumor formation. A loss of proper functioning of this protein leads to a development of vRD; however, a large variability in a phenotype of the disease and the onset of cutaneous findings, not necessarily in childhood, may provide a clinical diagnosis of the disease late in adulthood. We present a 52-year-old male in whom the diagnosis of vRD was proposed in the sixth decade of life, despite of multiple nodular lesions disseminated over the skin of the whole body and different neurological disturbances, not considered for a long time as manifestations of genodermatosis.<\/jats:p>","DOI":"10.1515\/bjmg-2016-0013","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T07:54:48Z","timestamp":1470210888000},"page":"95-102","source":"Crossref","is-referenced-by-count":1,"title":["Von recklinghausen disease: one patient \u2013 various problems"],"prefix":"10.1515","volume":"19","author":[{"given":"B","family":"Bergler-Czop","sequence":"first","affiliation":[{"name":"School of Medicine in Katowice, Medical University of Silesia in Katowice, Department of Dermatology, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Mizio\u0142ek","sequence":"additional","affiliation":[{"name":"Andrzej Miel\u0119cki Silesian Independent Public Clinical Hospital in Katowice, Department of Dermatology, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Brzezi\u0144ska-Wcis\u0142o","sequence":"additional","affiliation":[{"name":"School of Medicine in Katowice, Medical University of Silesia in Katowice, Department of Dermatology, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2016,8,2]]},"reference":[{"key":"2021040704415664011_j_bjmg-2016-0013_ref_001_w2aab3b8c43b1b7b1ab2b1b1Aa","unstructured":"Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC. Fakomatozy. In: Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC, Eds. Dermatologia. Lublin, Poland: Czelej. 2002; 793-797."},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_002_w2aab3b8c43b1b7b1ab2b1b2Aa","unstructured":"Sabol Z, Kipke-Sabol L. Neurofibromatosis type 1 (von Recklinghausen disease or peripheral neurofibromatosis): From phenotype to gene. Lijec Vjesn. 2005; 127(11-12): 303-311."},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_003_w2aab3b8c43b1b7b1ab2b1b3Aa","unstructured":"Abramowicz A, Gos M. Neurofibromin in neurofibromatosis type 1 - Mutations in NF1gene as a cause of disease. Dev Period Med. 2014; 18(3): 297-306."},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_004_w2aab3b8c43b1b7b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Shofty B, Constantini S, Ben-Shachar S. Advances in molecular diagnosis of neurofibromatosis type 1. Semin Pediatr Neurol. 2015; 22(4): 234-239.","DOI":"10.1016\/j.spen.2015.10.007"},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_005_w2aab3b8c43b1b7b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Ferner RE. Neurofibromatosis 1. In: Ferner RE, Huson SM, Evans DGR, Eds. Neurofibromatoses in Clinical Practice. London, UK: Springer-Verlag. 2011; 27-30.","DOI":"10.1007\/978-0-85729-629-0"},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_006_w2aab3b8c43b1b7b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Rasmussen S, Friedman JM. NF1 gene and neurofi-bromatosis 1. Am J Epidemiol. 2000; 151(1): 33-40.","DOI":"10.1093\/oxfordjournals.aje.a010118"},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_007_w2aab3b8c43b1b7b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Bunin GR, Needle M, Riccardi VM. Paternal age and sporadic neurofibromatosis 1: A case-control study and consideration of the methodologic issues. Genet Epidemiol. 1997; 14(5): 1507-1516.","DOI":"10.1002\/(SICI)1098-2272(1997)14:5<507::AID-GEPI5>3.0.CO;2-Y"},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_008_w2aab3b8c43b1b7b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Laycock-van Spyk S, Thomas N, Cooper DN, Upadhyaya M. Neurofibromatosis type 1-associated tumours: Their somatic mutational spectrum and pathogenesis. Hum Genomics. 2011; 5(6): 623-690.","DOI":"10.1186\/1479-7364-5-6-623"},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_009_w2aab3b8c43b1b7b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Yap YS, McPherson JR, Ong CK, Rozen SG, Teh BT, Lee AS, et al. The NF1 gene revisited - From bench to bedside. Oncotarget. 2014; 5(15): 5873-5892.","DOI":"10.18632\/oncotarget.2194"},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_010_w2aab3b8c43b1b7b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Brems H, Beert E, de Ravel T, Legius E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol. 2009; 10(5): 508-515.","DOI":"10.1016\/S1470-2045(09)70033-6"},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_011_w2aab3b8c43b1b7b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Venturin M, Guarnieri P, Natacci F, Stabile M, Tenconi R, Clementi M, et al. Mental retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes in 17q11.2. J Med Genet. 2004; 41(1): 35-41.","DOI":"10.1136\/jmg.2003.014761"},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_012_w2aab3b8c43b1b7b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Pasmant E, de Saint-Trivier A, Laurendeau I, Dieux-Coeslier A, Parfait B, Vidaud M, et al. Characterization of a 7.6-Mb germline deletion encompassing the NF1 locus and about a hundred genes in an NF1 contiguous gene syndrome patient. Eur J Hum Genet. 2008; 16(12): 1459-1466.","DOI":"10.1038\/ejhg.2008.134"},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_013_w2aab3b8c43b1b7b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Sharif S, Upadhyaya M, Ferner R, Majounie E, Shenton A, Baser M, et al. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations. J Med Genet. 2011; 48(4): 256-260.","DOI":"10.1136\/jmg.2010.081760"},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_014_w2aab3b8c43b1b7b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Upadhyaya M, Huson SM, Davies M, Thomas N, Chuzhanova N, Giovannini S, et al. An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet. 2007; 80(1): 140-151.","DOI":"10.1086\/510781"},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_015_w2aab3b8c43b1b7b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Rojnueangnit K, Xie J, Gomes A, Sharp A, Callens T, Chen Y, et al. High incidence of Noonan syndrome features including short stature and pulmonic stenosis in patients carrying NF1 missense mutations affecting p.Arg 1809: Genotype-phenotype correlation. Hum Mutat. 2015; 36(11): 1052-1063.","DOI":"10.1002\/humu.22832"},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_016_w2aab3b8c43b1b7b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Pinna V, Lanari V, Daniele P, Consoli F, Agolini E, Margiotti K, et al. p.Arg1809Cys Substitution in neu-rofibromin is associated with a distinctive NF1 phenotype without neurofibromas. Eur J Hum Genet. 2015; 23(8): 1068-1071.","DOI":"10.1038\/ejhg.2014.243"},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_017_w2aab3b8c43b1b7b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Kehrer-Sawatzki H. Neurofibromatosis type 1 without neurofibromas: Genotype-phenotype correlations in NF1. Hum Mutat. 2015; 36(11): doi: 10.1002\/humu.22669.","DOI":"10.1002\/humu.22669"},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_018_w2aab3b8c43b1b7b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Santoro C, Maietta A, Giugliano T, Melis D, Perrotta S, Nigro V, et al. Arg(1809) Substitution in neurofibromin: Further evidence of a genotype-phenotype correlation in neurofibromatosis type 1. Eur J Hum Genet. 2015; 23(11): 1460-1461.","DOI":"10.1038\/ejhg.2015.93"},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_019_w2aab3b8c43b1b7b1ab2b1c19Aa","unstructured":"Bayliss S, Mallory F, Bree A, Chern P. Dermatologia pediatryczna. In: Bayliss S, Mallory F, Bree A, Chern P, Eds. Diagnostyka i Leczenie. Lublin, Poland: Czelej. 2007; 387-389."},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_020_w2aab3b8c43b1b7b1ab2b1c20Aa","unstructured":"Baran E. Nowotwory sk\u00f3ry, klinika, patologia, leczenie. In: Baran E, Ed. L\u00f3dz, Poland: Galaktyka. 2008; 195-197."},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_021_w2aab3b8c43b1b7b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Sumner K, Crockett DK, Muram T, Mallempati K, Best H, Mao R. The SPRED1 variants repository for Legius syndrome. G3 (Bethesda). 2011; 1(6): 451-456.","DOI":"10.1534\/g3.111.000687"},{"key":"2021040704415664011_j_bjmg-2016-0013_ref_022_w2aab3b8c43b1b7b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Lodish MB, Stratakis CA. Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes. Best Pract Res Clin Endocrinol Metab. 2010; 24(3): 439-449.","DOI":"10.1016\/j.beem.2010.02.002"}],"container-title":["Balkan Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/bjmg\/19\/1\/article-p95.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciendo.com\/article\/10.1515\/bjmg-2016-0013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T09:20:06Z","timestamp":1617787206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciendo.com\/article\/10.1515\/bjmg-2016-0013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,8,2]]},"published-print":{"date-parts":[[2016,6,1]]}},"alternative-id":["10.1515\/bjmg-2016-0013"],"URL":"https:\/\/doi.org\/10.1515\/bjmg-2016-0013","relation":{},"ISSN":["1311-0160"],"issn-type":[{"value":"1311-0160","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,1]]}}}